Cisplatin induced higher levels of secondary necrosis/pyroptosis than paclitaxel in A549 cells, suggesting that cisplatin may provide additional advantages in treating lung cancers with high levels of GSDME expression [73]. This evidence concerns the gene GSDME and lung carcinoma.